The use of CA-50 radioimmunoassay inhibition test in the differential diagnosis of benign and malignant breast disease.
The role of the tumour marker CA-50 has been studied in the differential diagnosis of benign and malignant breast disease. Serum levels of CA-50 were determined by radioimmunoassay using a level of 17 units/ml as a cut-off. All 50 normal subjects and 22 of 24 patients (92%) with benign breast disease had CA-50 levels below 17 units/ml. By contrast, 15 of 36 patients (42%) with breast carcinoma had serum CA-50 levels above 17 units/ml (P less than 0.001). There was no clear correlation with tumour stage. The data suggest that CA-50 levels may help to differentiate benign and malignant diseases of the breast.
Hershman
M J
MJ
Department of Surgery, Royal Postgraduate Medical School, London.
Habib
N A
NA
Kelly
S B
SB
Beynon
J
J
Williamson
R C
RC
Davies
P W
PW
Wood
C B
CB
D000293:Adolescent; D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D001941:Breast Diseases / Q000175:diagnosis*; D001943:Breast Neoplasms / Q000175:diagnosis*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008875:Middle Aged; D011863:Radioimmunoassay
D015295:Antigens, Tumor-Associated, Carbohydrate